Drug intelligence / Profile preview

fexuprazan + sodium bicarbonate

Development stage: Unknown
Lead developer: Korea Arlico Pharm
Modality: Small Molecules
Administration: Oral

Overview

ALC-F011 is an incrementally modified drug (IMD) developed by **Korea Arlico Pharm** for the treatment of acid-related digestive disorders, such as gastroesophageal reflux disease (GERD). It is a fixed-dose combination consisting of **fexuprazan**, a potassium-competitive acid blocker (P-CAB), and **sodium bicarbonate**, an antacid. Fexuprazan provides rapid and sustained suppression of gastric acid by reversibly inhibiting the H+/K+-ATPase enzyme in gastric parietal cells. The addition of sodium bicarbonate is intended to provide an immediate neutralizing effect on existing gastric acid, potentially accelerating the onset of symptom relief and enhancing the stability of the P-CAB component. The drug is currently undergoing Phase 1 clinical trials in South Korea to evaluate its pharmacokinetic profile and safety compared to its individual components.

Other names: Fexuprazan/Sodium Bicarbonate

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on fexuprazan + sodium bicarbonate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fexuprazan + sodium bicarbonate.

Explore the full profile